

Factsheet

© 2009 Axentis Pharma AG
Limmatquai 138, 8001 Zurich
phone: +41 44 202 7878
board@axentispharma.com



THE COMPANY

Axentis Pharma is a respiratory specialty pharmaceutical company whose core competence is the combination of a fully patented, encapsulating drug delivery system with already established and well-characterized therapeutic agents.

Based on significant expertise in research and business development, the company is creating a portfolio of products through internal development and acquisition/in-licensing activities.

The mission behind this approach is the company's dedication to build a sustainable respiratory product pipeline with the view to commercially surpass already existing therapies.

The core of Axentis Pharma's current strategy involves combining success with innovation. Successful and established drugs with proven efficacy are formulated or delivered in novel and innovative ways. This approach helps to improve patient care, patient compliance and, hence, efficacy of the medication while reducing adverse side effects.

At Axentis Pharma, innovation advances gradually and steadily, building on proven success.

THE FOUNDERS

At Axentis Pharma, it is not just innovation that builds on proven success – its management team does too:

Helmut Brunar, PhD, CEO and Chairman

Previous to his position as Vice-President for Research and Development at Kwizda Pharma, Austria, Dr. Brunar held research and managerial positions at international



pharmaceutical companies including Sandoz, Baxter and Boehringer-Ingelheim.

Dr. Brunar has worked in several therapeutic areas including oncology, pulmonology, and

hematology. His academic

merits reach from a degree in chemistry from the Vienna Technical University to a PhD from the same University, and a fellowship from the California Institute of Technology, USA.

Hans Schreier, PhD, Chief Scientist

Dr. Schreier is an experienced entrepreneur with an impressive track record that includes being co-founder of ARYx Therapeutics, Inc., Fremont, California. His expertise lies in



designing drug delivery systems, specifically liposome technology, pulmonary drug delivery and non-viral gene therapy. He holds several patents and has published over 70 articles, reviews and book chapters since 1982. He

also recently edited a book entitled 'Drug Targeting Technology'.

Factsheet

© 2009 Axentis Pharma AG
Limmatquai 138, 8001 Zurich
phone: +41 44 202 7878
board@axentispharma.com



THE TECHNOLOGY

Current technological progress at Axentis Pharma focuses on cystic fibrosis, an inherited chronic disease that affects the lungs and digestive system.

Fluidosomes™ - tobramycin

The company's Fluidosomes™ - tobramycin is an effective treatment for lung infections – the most devastating clinical consequence of cystic fibrosis. Axentis Pharma has encapsulated the active compound tobramycin into biologically inactive liposomes, being the carrier of the drug for a prolonged, high local drug concentration via a standard nebulizer. The same technology can be applied also for other respiratory and pulmonary infections and obstructions which have all together a very large and steady increasing market size of millions of patients worldwide.

A WORTHWHILE INVESTMENT



Kurt Bushati, Axentis Pharma Shareholder:

Why do I believe in Axentis' success?

“Streamlined, smart and dedicated – these are attributes that I personally associate with Axentis Pharma. It is a company that focuses the skills and know-how of an experienced and committed management team on achieving two goals: improving quality of life for many millions of people with respiratory tract complications and generating a satisfying return on investment for early investors.

To my mind, Axentis Pharma's life saving approach seems a worthwhile investment.”

CONTACTS

Axentis Pharma AG
Limmatquai 138
8001 Zurich
Switzerland

phone: +41 44 202 7878
board@axentispharma.com
www.axentispharma.com